Phase 1 Trial Shows IPF Treatment BBT-877 Is Safe While Lowering Blood Levels of Fibrotic Molecules
Senior Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how data from a phase 1 trial shows the potential IPF treatment BBT-877 is safe, and lowers blood levels of fibrotic molecules.
Are you interested in learning more about Pulmonary Fibrosis? If so, please visit pulmonaryfibrosisnews.com/
What do you think about this news? Listen to this flash briefing episode and share your thoughts in the comment section below!
Sorry, there were no replies found.
Log in to reply.